ketoconazole has been researched along with Malaria in 7 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To predict the optimal chemoprophylactic dose of mefloquine in infants of 5-10 kg using physiologically based pharmacokinetic (PBPK) and clinical effectiveness models." | 5.51 | Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children. ( Cleary, Y; Johnson, TN; Parrott, N; Reigner, B; Smith, JR; Toovey, S, 2019) |
| "To predict the optimal chemoprophylactic dose of mefloquine in infants of 5-10 kg using physiologically based pharmacokinetic (PBPK) and clinical effectiveness models." | 1.51 | Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children. ( Cleary, Y; Johnson, TN; Parrott, N; Reigner, B; Smith, JR; Toovey, S, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cross, RM | 1 |
| Flanigan, DL | 1 |
| Monastyrskyi, A | 1 |
| LaCrue, AN | 1 |
| Sáenz, FE | 1 |
| Maignan, JR | 1 |
| Mutka, TS | 1 |
| White, KL | 1 |
| Shackleford, DM | 2 |
| Bathurst, I | 1 |
| Fronczek, FR | 1 |
| Wojtas, L | 1 |
| Guida, WC | 1 |
| Charman, SA | 2 |
| Burrows, JN | 1 |
| Kyle, DE | 1 |
| Manetsch, R | 1 |
| O' Neill, PM | 1 |
| Stocks, PA | 1 |
| Sabbani, S | 1 |
| Roberts, NL | 1 |
| Amewu, RK | 1 |
| Shore, ER | 1 |
| Aljayyoussi, G | 1 |
| Angulo-Barturén, I | 1 |
| Belén, M | 1 |
| Bazaga, SF | 1 |
| Martínez, MS | 1 |
| Campo, B | 1 |
| Sharma, R | 1 |
| Ryan, E | 1 |
| Chen, G | 1 |
| Davies, J | 1 |
| Nixon, GL | 1 |
| Biagini, GA | 1 |
| Ward, SA | 1 |
| Johnson, TN | 1 |
| Cleary, Y | 1 |
| Parrott, N | 1 |
| Reigner, B | 1 |
| Smith, JR | 1 |
| Toovey, S | 1 |
| Chandra, R | 1 |
| Puri, SK | 1 |
| Tripathi, R | 2 |
| Rizvi, A | 1 |
| Pandey, SK | 1 |
| Dwivedi, H | 1 |
| Saxena, JK | 1 |
| Awasthi, A | 1 |
| Dutta, GP | 1 |
| Raether, W | 1 |
| Seidenath, H | 1 |
7 other studies available for ketoconazole and Malaria
| Article | Year |
|---|---|
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
Topics: Animals; Antimalarials; Humans; Inhibitory Concentration 50; Malaria; Mice; Microsomes, Liver; Paras | 2014 |
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
Topics: Administration, Oral; Animals; Antimalarials; Disease Models, Animal; Drug Stability; Humans; Inhibi | 2018 |
Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children.
Topics: Adult; Age Factors; Antimalarials; Child; Child, Preschool; Drug Dosage Calculations; Drug Interacti | 2019 |
Arteether resistance reversal by ketoconazole/fluconazole in rodent malaria parasite Plasmodium vinckei.
Topics: Animals; Antifungal Agents; Antimalarials; Artemisinins; Drug Resistance; Drug Therapy, Combination; | 2015 |
Ketoconazole, a cytochrome P(450) inhibitor can potentiate the antimalarial action of α/β arteether against MDR Plasmodium yoelii nigeriensis.
Topics: Animals; Antimalarials; Artemisinins; Chloroquine; Drug Resistance, Multiple; Drug Synergism; Drug T | 2013 |
Mefloquine resistance reversal action of ketoconazole - a cytochrome P450 inhibitor, against mefloquine-resistant malaria.
Topics: Animals; Antimalarials; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug R | 2005 |
Ketoconazole and other potent antimycotic azoles exhibit pronounced activity against Trypanosoma cruzi, Plasmodium berghei and Entamoeba histolytica in vivo.
Topics: Amebiasis; Animals; Antifungal Agents; Chagas Disease; Entamoeba histolytica; Entamoebiasis; Ketocon | 1984 |